Results 11 to 20 of about 13,492 (207)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib [PDF]

Pharmaceutics, 2020
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse
Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen-de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L. W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen, Alex Sparreboom, Sander Bins   +16 more
doaj   +3 more sources

Probenecid Pre-treatment Downregulates the Kidney Cl-/HCO3- Exchanger (Pendrin) and Potentiates Hydrochlorothiazide-Induced Diuresis [PDF]

Frontiers in Physiology, 2018
Background: Probenecid is a uricosuric agent that in addition to exerting a positive ionotropic effect in the heart, blocks the ATP transporter Pannexin 1 and inhibits the Cl-/HCO3- exchanger, pendrin.
Sharon Barone, Sharon Barone, Jie Xu, Jie Xu, Kamyar Zahedi, Kamyar Zahedi, Marybeth Brooks, Manoocher Soleimani, Manoocher Soleimani, Manoocher Soleimani   +9 more
doaj   +2 more sources

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers [PDF]

Current Therapeutic Research, 2014
Background: Olmesartan is an angiotensin II receptor antagonist and is effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricemic agent for the treatment of hyperuricemia and gout. Objective: The
Kun-Yan Li, PhD, Yu Qiu, MS, Yun Jiang, BS, Chen-Hui Luo, MS, Xiao-Ping Lin, BS, Jing Wang, BS, Nong Yang, MS   +6 more
doaj   +3 more sources

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

Viruses, 2023
Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We conducted
David E. Martin, Neelam Pandey, Purvi Chavda, Gurpreet Singh, Rakesh Sutariya, Frederic Sancilio, Ralph A. Tripp   +6 more
doaj   +2 more sources

Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation

Biomedicines, 2023
Probenecid is an old uricosuric agent used in clinics to treat gout and reduce the renal excretion of antibiotics. In recent years, probenecid has gained attention due to its ability to interact with membrane proteins such as TRPV2 channels, organic ...
Claudia García-Rodríguez, Paula Mujica, Javiera Illanes-González, Araceli López, Camilo Vargas, Juan C. Sáez, Arlek González-Jamett, Álvaro O. Ardiles   +7 more
doaj   +2 more sources

Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.

PLoS ONE, 2020
Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes.
Evan Onusko, Michael R McDermott, Nathan Robbins, Guansheng Liu, Evangelia G Kranias, Jack Rubinstein, Sheryl E Koch   +6 more
doaj   +2 more sources

Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease

Physiological Reports, 2023
Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities. Cystic fluid contains a high level of ATP that, among other effects, leads to a reduced reabsorption of electrolytes in cyst‐lining cells ...
Sergey N. Arkhipov, D'Anna L. Potter, Regina F. Sultanova, Daria V. Ilatovskaya, Peter C. Harris, Tengis S. Pavlov   +5 more
doaj   +2 more sources

Towards pharmacokinetic boosting of phenoxymethylpenicillin (penicillin-V) using probenecid for the treatment of bacterial infections

Scientific Reports
In the face of increasing antimicrobial tolerance and resistance there is a global obligation to optimise oral antimicrobial dosing strategies including narrow spectrum penicillins, such as penicillin-V.
Richard C. Wilson, Alaa Riezk, Paul Arkell, Damien Ming, Ryan Armiger, Victoria Latham, Mark J. Gilchrist, Anne-Grete Märtson, William W. Hope, Alison H. Holmes, Timothy M. Rawson   +10 more
doaj   +2 more sources

Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells [PDF]

Viruses
In human and non-human primates, filoviruses, e.g., Ebolaviruses, cause severe hemorrhagic fever for which there are few therapeutic options. While there are licensed vaccines and therapeutics for Ebola virus disease, there is no approved vaccine or ...
Kendra Alfson, Ricardo Carrion, Ralph A. Tripp, Chris Cirimotich, David E. Martin   +4 more
doaj   +2 more sources

Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers

Drug Design, Development and Therapy, 2016
Yi-fan Zhang,1 Xiao-jian Dai,1 Yong Yang,1 Xiao-yan Chen,1 Ting Wang,2 Yun-biao Tang,3 Cheng-yuan Tsai,4 Li-wen Chang,4 Yu-ting Chang,4 Da-fang Zhong1 1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of ...
Zhang YF, Dai XJ, Yang Y, Chen XY, Wang T, Tang YB, Tsai CY, Chang LW, Chang YT, Zhong DF   +9 more
doaj   +1 more source